Hinge Bio to receive $10 million upfront and is eligible to receive $95 million for the SLE indication and additional payments for other indications; includes contingent R&D investment, tiered sales ...

Recent noteworthy reports on diffuse large B-cell lymphoma (DLBCL) include positive survival results with an antibody-drug conjugate in relapsed/refractory disease, FDA issues with a randomized trial, ...

Aera Therapeutics, a biotechnology company harnessing next-generation enabling delivery technologies and precision payloads to unlock the full potential of genetic medicines, today presented ...

B cell development in swine presents a unique model within mammalian immunology. In contrast to traditional murine and human systems, swine exhibit notable differences in the temporal order of heavy ...

New findings show that the stage of normal cell development at which B cells transform into leukemic cells impacts treatment outcomes for pediatric patients with B-cell acute lymphoblastic leukemia (B ...

The emerging role of SETD2 in regulating immune cell function is shedding light on potential therapeutic strategies for a range of immune-related diseases. As a key methyltransferase, SETD2 ...